Resmetirom is an oral medication taken once daily that works by targeting thyroid hormone receptors in the liver. It is being studied for treating non-alcoholic steatohepatitis (NASH) with cirrhosis. This medication aims to improve liver function and prevent complications in patients with liver disease. It may help reduce liver-related health issues and cardiovascular problems in patients with NASH cirrhosis.

Non-alcoholic Steatohepatitis (NASH) – A progressive liver disease characterized by fat accumulation in the liver accompanied by inflammation and cell damage. The condition develops when excess fat builds up in liver cells, leading to inflammation and eventually scarring of liver tissue. NASH can progress slowly over years, causing the liver to become enlarged and less functional. The disease typically shows no symptoms in its early stages but may cause fatigue and pain in the upper right abdomen as it advances. When NASH progresses significantly, it can lead to cirrhosis, where healthy liver tissue is replaced by scar tissue.

Cirrhosis – A chronic liver condition characterized by extensive scarring of liver tissue that develops when healthy liver cells are gradually replaced by scar tissue. This scarring process, called fibrosis, occurs as the liver tries to repair and replace damaged cells. As cirrhosis progresses, the liver becomes increasingly hardened and lumpy, making it more difficult for the organ to function properly. The condition develops slowly over many years and can be caused by various factors or diseases affecting the liver.